Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Tumor type

Lung Cancer

OncoTree code LUNG · 9 articles

Clinical · Molecular biology

Biomarker Detection of Lung Cancers Before Clinical Symptoms or the Use of Traditional Imaging Methods in the ITALUNG Trial

Bisanzi S, Russo V, Carrozzi L, et al.

International journal of molecular sciences

The ITALUNG trial, a randomized controlled study, evaluated low-dose computed tomography (LDCT) for lung cancer screening in over 3100 high-risk individuals. This study also analyzed the performance of a biomarker panel (loss of heterozygosity/microsatellite instability and circulating free DNA) in blood and sputum samples. The panel demonstrated high sensitivity for detecting lung cancers, even in pre-diagnostic samples collected several years before clinical diagnosis. These biomarkers may be associated with carcinogenic field effects and early tumor presence.

Molecular biology · Clinical

Multi-omic cell free DNA profiles of cerebral spinal fluid from lung cancer metastasis to the brain

Chen T, Bai X, Burnside G, et al.

NAR cancer

This study investigates cell-free DNA (cfDNA) profiles in the cerebrospinal fluid (CSF) of patients with lung cancer brain metastases. Using nanopore single-molecule sequencing, researchers analyzed fragmentation, methylation, and hydroxymethylation patterns of cfDNA. Significant differences were observed between cancer patients and healthy controls, including enriched mono-nucleosome levels and higher mono-/trinucleosome ratios in cancer patients. Distinct methylation and hydroxymethylation profiles were also identified, with a significantly lower degree of hydroxymethylation in cancer patients. These findings suggest that CSF cfDNA exhibits unique characteristics that could serve as biomarkers for non-small cell lung cancer brain metastases.

Clinical · Molecular biology

Rare Fusions, Real Targets: Ultraprecision Oncology in Lung Cancer

Le X, Wolf J

Cancer discovery

This article highlights the significance of rare and ultrarare gene fusions, beyond established ones like ALK and ROS1, in lung cancer. It emphasizes that emerging fusions, involving receptor tyrosine kinases or their ligands, such as EGFR-SHC1, unveil novel mechanisms of oncogenic activation. These discoveries are propelling precision medicine towards an era of "ultraprecision" oncology, enabling increasingly individualized treatment strategies for cancer patients.

Clinical · Molecular biology

Multi-omics profiling unveils biological and clinical insights into pulmonary sarcomatoid carcinoma

Sun L, Wang J, Yan Y, et al.

Cell reports. Medicine

This study conducted a comprehensive multi-omics analysis of pulmonary sarcomatoid carcinoma (PSC), a rare and aggressive lung cancer. Integrating whole-exome sequencing, transcriptomic, proteomic, and phosphoproteomic data from 86 patients, alongside single-cell RNA sequencing, researchers characterized this poorly understood disease. They identified an elevated ferroptosis suppression signature, making tumors vulnerable to targeting FTL and SLC3A2. The study also revealed distinct patient subtypes based on proteomic profiling and highlighted the role of epithelial-mesenchymal transition in tumor progression and immunotherapy resistance.

Clinical · Molecular biology · Bioinfo & AI

Enrichment of SMARCA4 mutations in lung carcinomas presenting as cancer of unknown primary

Martinot T, Schonewille LHN, Ruano D, et al.

Lung cancer (Amsterdam, Netherlands)

This study investigates a simplified approach to identify lung origin in cancers of unknown primary (CUP). Researchers found that the presence of SMARCA4 mutations, combined with a history of smoking, is strongly associated with lung-origin CUP (CUP-Lung). This combination offers a 76% probability of lung origin, even without detectable pulmonary involvement. This method could serve as a surrogate for whole-genome sequencing (WGS) to guide organ-directed treatments.

Clinical · Molecular biology · Bioinfo & AI

Blood-based DNA methylation marker model for short-term and long-term lung cancer risk prediction

Bhardwaj M, Sun YQ, Frick C, et al.

BMC medicine

A novel study developed and validated a blood-based DNA methylation marker model (BBDMM) for predicting lung cancer risk. This model utilizes informative CpG sites identified through epigenome-wide association studies (EWAS). It was developed and internally validated in a German cohort of over 2,400 participants, then externally validated in Norwegian cohorts. The BBDMM demonstrated excellent discriminatory capacity, with AUCs of 0.84 and 0.85, and predictive stability over periods up to 18 years before diagnosis. These findings suggest significant potential for improving lung cancer screening.

Molecular biology · Bioinfo & AI

Early Lung Cancer Detection Using Nucleotide Transition Probabilities in Plasma Cell-Free DNA

Ji J, Xue R, Zhang X, et al.

Cancer epidemiology, biomarkers & prevention

Lung cancer is a lethal malignancy urgently requiring effective early detection strategies, as current cfDNA-based approaches often lack sensitivity in early stages. This study developed a novel computational feature, First-Order Transition Probability (FOTP), to capture nucleotide sequential dependencies within cfDNA fragments. Using low-pass whole-genome sequencing data, an SVM model trained with FOTP achieved 73.9% sensitivity for stage I and 81.8% for stage II lung cancer at 95% specificity. This method, which significantly outperforms existing fragmentomic features, is biologically interpretable and offers a scalable strategy for early cancer screening.

Bioinfo & AI

Effects of Non-IID Distributions in Lung Cancer Data on Survival Prediction with Federated Ensemble Learning

Weber L, Hauschild AC, Altenbuchinger M, et al.

Studies in health technology and informatics

This study investigates the impact of non-independent and identically distributed (Non-IID) data on the performance of Federated Learning (FL) models for survival prediction using lung cancer data. Researchers compared Random Forest (RF) and AdaBoost algorithms across various scenarios of data distribution shifts among clients. The findings indicate that both algorithms experienced significant performance degradation under highly non-IID conditions. Notably, Random Forest consistently outperformed AdaBoost in these challenging scenarios. The developed FL algorithm holds potential for model personalization and fine-tuning, with broader applicability to other clinical datasets.

Molecular biology

'Upcycling pathology': targeted next-generation sequencing is feasible in re-purposed haematoxylin and eosin and immunostained formalin-fixed paraffin-embedded sections in lung cancer biopsies

Cheng XM, Ooi LY, Tan GS, et al.

Pathology

Lung cancer biopsies often yield limited material, complicating predictive molecular testing and sometimes necessitating re-biopsy. This study investigated the feasibility of repurposing routine diagnostic slides, specifically H&E-stained and immunostained sections, for molecular analysis. From 40 lung biopsy specimens, DNA extraction and targeted next-generation sequencing were successfully performed for 33 cases. The results demonstrated high concordance of detected variants, suggesting this approach is a viable alternative for molecular testing.